Sustained release of TGF-β1 from biodegradable microparticles prepared by a new green process in CO2 medium

Swed, Amin; Cordonnier, Thomas; Dénarnaud, Alison; Boyer, Cinda M.; Guicheux, Jérôme; Weiss, Pierre; Boury, Frank

doi:10.1016/j.ijpharm.2015.07.043

Cited by 10 publications

(7 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When a mixture of PLGA-COOH and PLGA-COOR was tested (Formulation 10), only 12% encapsulated lysozyme was successfully released. The lack of protein release from PLGA particles containing uncapped carboxylic end groups has been previously reported [38,41,63]. Concurrent measurement of zeta-potentials during the release study offered a possible explanation for this observation.…”

Section: In Vitro Protein Releasesupporting

confidence: 53%

“…In vitro cytotoxicity of unloaded PLGA/PEG-PLGA nanoparticles was evaluated using a resazurinbased assay adapted from Swed et al [41]. NIH3T3 mouse fibroblast cell line was cultured at 37 °C and 5% CO 2 in medium supplemented with 10% FBS and 1% penicillin/streptomycin, and replaced Cell viability was estimated from the fluorescence intensity of the reduced product of resazurin, called resorufin, which was measured using a ClarioStar microplate fluorometer (BMG Labtech GmbH, Ortenberg, Germany) at 545 nm excitation and 600 nm emission.…”

Section: In Vitro Cytotoxicity Of Nanoparticlesmentioning

confidence: 99%

“…Secondly, it has been used to precipitate many proteins without causing their denaturation [25,38,45,46]. P188 was added due to its ability to refold any unfolded protein [47] and also to reduce protein adsorption to the hydrophobic PLGA following encapsulation, which in turn may allow for greater cumulative release [38,48].…”

Section: Lysozyme and Sdf-1α Precipitationmentioning

confidence: 99%

See 2 more Smart Citations

Development of a non-toxic and non-denaturing formulation process for encapsulation of SDF-1α into PLGA/PEG-PLGA nanoparticles to achieve sustained release

Mansor

Najberg

et al. 2018

European Journal of Pharmaceutics and Biopharmaceutics

Self Cite

View full text Add to dashboard Cite

Chemokines are known to stimulate directed migration of cancer cells. Therefore, the strategy involving gradual chemokine release from polymeric vehicles for trapping cancer cells is of interest. In this work, the chemokine stromal cell-derived factor-1α (SDF-1α) was encapsulated into nanoparticles composed of poly-(lactic-co-glycolic acid) (PLGA) and a polyethylene glycol (PEG)-PLGA co-polymer to achieve sustained release. SDF-1α, and lysozyme as a model protein, were firstly precipitated to promote their stability upon encapsulation. A novel phase separation method utilising a non-toxic solvent in the form of isosorbide dimethyl ether was developed for the individual encapsulation of SDF-1α and lysozyme precipitates. Uniform nanoparticles of 200-250 nm in size with spherical morphologies were successfully synthesised under mild formulation conditions and conveniently freeze-dried in the presence of hydroxypropyl-β-cyclodextrin as a stabiliser. The effect of PLGA carboxylic acid terminal capping on protein encapsulation efficiency and release rate was also explored. Following optimisation, sustained release of SDF-1α was achieved over a period of 72 h. Importantly, the novel encapsulation process was found to induce negligible protein denaturation. The obtained SDF-1α nanocarriers may be subsequently incorporated within a hydrogel or other scaffolds to establish a chemokine concentration gradient for the trapping of glioblastoma cells.

show abstract

Section: In Vitro Protein Releasesupporting

confidence: 53%

Section: In Vitro Cytotoxicity Of Nanoparticlesmentioning

confidence: 99%

Section: Lysozyme and Sdf-1α Precipitationmentioning

confidence: 99%

See 1 more Smart Citation

Development of a non-toxic and non-denaturing formulation process for encapsulation of SDF-1α into PLGA/PEG-PLGA nanoparticles to achieve sustained release

Mansor

Najberg

et al. 2018

European Journal of Pharmaceutics and Biopharmaceutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…The favorable biocompatibility of PLA has been utilized for combined drug delivery systems and diagnostics [22,67]. For example, polymeric micelles (mean size of 20nm) accumulated in glioma tumors in mice 24 hr after intravenous administration [68].…”

Section: Polylactic Acid In Theranosticsmentioning

confidence: 99%

Biocompatibility, biodegradation and excretion of polylactic acid (PLA) in medical implants and theranostic systems

Silva

Kaduri

Poley

et al. 2018

Chemical Engineering Journal

610

329

View full text Add to dashboard Cite

Polylactic acid (PLA) is the most commonly used biodegradable polymer in clinical applications today. Examples range from drug delivery systems, tissue engineering, temporary and long-term implantable devices; constantly expanding to new fields. This is owed greatly to the polymer's favorable biocompatibility and to its safe degradation products. Once coming in contact with biological media, the polymer begins breaking down, usually by hydrolysis, into lactic acid (LA) or to carbon dioxide and water. These products are metabolized intracellularly or excreted in the urine and breath. Bacterial infection and foreign-body inflammation enhance the breakdown of PLA, through the secretion of enzymes that degrade the polymeric matrix. The biodegradation occurs both on the surface of the polymeric device and inside the polymer body, by diffusion of water between the polymer chains. The median half-life of the polymer is 30 weeks; however, this can be lengthened or shortened to address the clinical needs. Degradation kinetics can be tuned by determining the molecular composition and the physical architecture of the device. Using L-or D-chirality of the LA will greatly slow or lengthen the degradation rates, respectively. Despite the fact that this polymer is more than 150 years old, PLA remains a fertile platform for biomedical innovation and fundamental understanding of how artificial polymers can safely coexist with biological systems.

show abstract

“…Non-toxic solvents such as glycofurol and isosorbide dimethyl ether (DMI) have also been explored. 76 …”

Section: Bottom-up Approachesmentioning

confidence: 99%

Approaches for building bioactive elements into synthetic scaffolds for bone tissue engineering

Kesireddy

Kasper

2016

J. Mater. Chem. B

View full text Add to dashboard Cite

Bone tissue engineering (BTE) is emerging as a possible solution for regeneration of bone in a number of applications. For effective utilization, BTE scaffolds often need modifications to impart biological cues that drive diverse cellular functions such as adhesion, migration, survival, proliferation, differentiation, and biomineralization. This review provides an outline of various approaches for building bioactive elements into synthetic scaffolds for BTE and classifies them broadly under two distinct schemes; namely, the top-down approach and the bottom-up approach. Synthetic and natural routes for top-down approaches to production of bioactive constructs for BTE, such as generation of scaffold-extracellular matrix (ECM) hybrid constructs or decellularized and demineralized scaffolds, are provided. Similarly, traditional scaffold-based bottom-up approaches, including growth factor immobilization or peptide-tethered scaffolds, are provided. Finally, a brief overview of emerging bottom-up approaches for generating biologically active constructs for BTE is given. A discussion of the key areas for further investigation, challenges, and opportunities is also presented.

show abstract

Sustained release of TGF-β1 from biodegradable microparticles prepared by a new green process in CO2 medium

Cited by 10 publications

References 56 publications

Development of a non-toxic and non-denaturing formulation process for encapsulation of SDF-1α into PLGA/PEG-PLGA nanoparticles to achieve sustained release

Development of a non-toxic and non-denaturing formulation process for encapsulation of SDF-1α into PLGA/PEG-PLGA nanoparticles to achieve sustained release

Biocompatibility, biodegradation and excretion of polylactic acid (PLA) in medical implants and theranostic systems

Approaches for building bioactive elements into synthetic scaffolds for bone tissue engineering

Contact Info

Product

Resources

About